Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The Learning Portal will be under maintenance Monday, 6 December between 6 AM and 5 PM EST. Portal functionality will be unavailable during this window.
We apologize for any inconvenience caused during this time.
Posted 15 May 2012 | By Alexander Gaffney, RAC
The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) announced 14 May it has established a concept paper and business paper for a new expert working group (EWG) aiming to develop guidance on rodent carcinogenicity testing.
"The aim of this new topic is to introduce a more comprehensive and integrated approach to addressing the risk of human carcinogenicity of pharmaceuticals, and also to clarify and update, without compromising safety, the criteria for deciding whether the conduct of a two-year rodent carcinogenicity study of a given pharmaceutical would add value to this risk assessment," wrote ICH in a statement.
The EWG, S1: Rodent Carcinogenicity Studies for Human Pharmaceuticals, said it hopes to develop a "crisply defined" plan detailing how the working group would impact the efforts of other groups working on carcinogenicity testing topics, including S1A: Need for Carcinogenicity Studies in Pharmaceuticals and S1B: Testing for Carcinogenicity of Pharmaceuticals.
The S1 EWG said in its concept paper that it sees a need to "help determine whether aspects of a pharmaceutical's pharmacology and toxicology, as current evaluated in nonclinical programs, can be used to adequately assess the degree of carcinogenic risk short of conduct two-year rodent bioassays."
The group expects to modify the existing ICH S1 rodent carcinogenicity testing Guidelines, but first must surmount a number of issues, including the need for additional data, the limits of analytical studies, process alignment between sponsors and regulatory authorities, clear definitions of endpoints and the use of secondary pharmacologic characteristics to predict outcomes.
ICH - The Steering Committee endorses the establishment of an S1 EWG
ICH Safety Guidelines
Concept Paper - S1: Rodent Carcinogenicity Studies for Human Pharmaceuticals
Tags: Carcinogenicity, Rodent, Expert Working Group, EWG, Safety Guideline, S1, Harmonisation, harmonization, Latest News
Regulatory Focus newsletters
All the biggest regulatory news and happenings.